Laboratory Corporation of America Holdings (Labcorp) has been experiencing a significant upward trend, with its stock price climbing 25.6% this year. This is primarily due to innovative initiatives and a positive earnings snapshot. In a clear testament to their confidence, Morgan Stanley has raised their price target for Labcorp to $283, affirming their 'Overweight' rating. Similarly, Baird adjusted its price target to $290 from $268, maintaining an outperform rating. Labcorp has drawn attention for their introduction of Labcorp Whole Health Solutions and a 1000+ Biomarker Platform, both aimed at supporting holistic care. This highlights Labcorp's innovative approach and commitment to revolutionizing healthcare testing. Another key driver is the acquisition of select assets from BioReference Health's oncology and clinical testing services. There have been misses in some quarters, leading to a revenue rise but a slight shortfall of expectations. Regardless, the company continues to provide value for shareholders via regular dividends and its robust growth outlook. Some concerns, like CFO Glenn Eisenberg's retirement and CEO Adam Schechter selling stocks, have barely affected investor sentiment, indicating Labcorp's strong market position.
Laboratory Corporation of America Holdings LH News Analytics from Sat, 25 Jul 2020 07:00:00 GMT to Wed, 18 Jun 2025 12:28:00 GMT -
Rating 9
- Innovation 8
- Information 7
- Rumor -1
